Literature DB >> 24184801

Dysregulation of the mTOR pathway in p53-deficient mice.

Olga V Leontieva1, Liliya R Novototskaya1, Geraldine M Paszkiewicz1, Elena A Komarova1, Andrei V Gudkov1, Mikhail V Blagosklonny1.   

Abstract

Mammalian or mechanistic target of rapamycin (mTOR) is involved in growth, aging, and age-related diseases including cancer. There is an extensive cross talk between p53 and mTOR. In cell culture, p53 inhibits the mTOR pathway in a cell type-dependent manner. p53-deficient mice develop pro-inflammation and cancer. We have shown that rapamycin delayed cancer and extended lifespan, thus partially substituting for p53. Here we show that a marker of mTOR activity, phosphorylated S6 (p-S6), is increased in the hearts of p53-deficient mice. Furthermore, cardiac p-S6 correlated with body weight. Also, p53(-/-) mice were slightly hyperinsulinemic with a tendency to elevated IGF-1. Radiation exacerbated the difference between IGF-1 levels in normal and p53(-/-) mice. Noteworthy, radiation induced Thr-308 Akt phosphorylation in the livers (but not in the hearts) of both p53(+/+) and p53(-/-) mice. Simultaneously, radiation decreased p-S6 in the livers of normal mice, consistent with the negative effect of p53 on mTOR. Our data indicate that the activity of mTOR is increased in some but not all tissues of p53(-/-) mice, associated with the tendency to increased insulin and IGF-1 levels. Therefore, the absence of p53 may create oncophilic microenvironment, favoring cancer.

Entities:  

Keywords:  aging; cancer; inflammation; mTOR; p53; rapalog; rapamycin; senescence

Mesh:

Substances:

Year:  2013        PMID: 24184801      PMCID: PMC3912042          DOI: 10.4161/cbt.26947

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  88 in total

1.  Regulation of PTEN transcription by p53.

Authors:  V Stambolic; D MacPherson; D Sas; Y Lin; B Snow; Y Jang; S Benchimol; T W Mak
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

2.  Inflammation and p53: A Tale of Two Stresses.

Authors:  Andrei V Gudkov; Katerina V Gurova; Elena A Komarova
Journal:  Genes Cancer       Date:  2011-04

3.  Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice.

Authors:  S D Hursting; S N Perkins; J M Phang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

Review 4.  Dangerous habits of a security guard: the two faces of p53 as a drug target.

Authors:  Andrei V Gudkov; Elena A Komarova
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

5.  CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis.

Authors:  Varun V Prabhu; Noel A Warfel; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

6.  DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.

Authors:  Olga V Leontieva; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

7.  If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.

Authors:  Vladimir N Anisimov; Lev M Berstein; Irina G Popovich; Mark A Zabezhinski; Peter A Egormin; Tatiana S Piskunova; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Irina G Kovalenko; Tatiana E Poroshina
Journal:  Aging (Albany NY)       Date:  2011-02       Impact factor: 5.682

8.  Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2012-07       Impact factor: 5.682

9.  Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet.

Authors:  O V Leontieva; G Paszkiewicz; Z N Demidenko; M V Blagosklonny
Journal:  Cell Death Dis       Date:  2013-01-24       Impact factor: 8.469

10.  p53 induces transcriptional and translational programs to suppress cell proliferation and growth.

Authors:  Fabricio Loayza-Puch; Jarno Drost; Koos Rooijers; Rui Lopes; Ran Elkon; Reuven Agami
Journal:  Genome Biol       Date:  2013-04-17       Impact factor: 13.583

View more
  21 in total

Review 1.  Geroconversion: irreversible step to cellular senescence.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

2.  Quantitative analysis of male germline stem cell differentiation reveals a role for the p53-mTORC1 pathway in spermatogonial maintenance.

Authors:  Mulin Xiong; Ianina C Ferder; Yasuyo Ohguchi; Ning Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  A role for cellular senescence in birth timing.

Authors:  Jeeyeon M Cha; David M Aronoff
Journal:  Cell Cycle       Date:  2017-09-25       Impact factor: 4.534

Review 4.  Mechanistic target of rapamycin signaling in mouse models of accelerated aging.

Authors:  Jin Young Lee; Brian K Kennedy; Chen-Yu Liao
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-01-01       Impact factor: 6.053

Review 5.  Phosphorylation of Akt at the C-terminal tail triggers Akt activation.

Authors:  Pengda Liu; Zhiwei Wang; Wenyi Wei
Journal:  Cell Cycle       Date:  2014-06-16       Impact factor: 4.534

6.  Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.

Authors:  Olga V Leontieva; Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

7.  Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Authors:  Lorena Landuzzi; Marianna L Ianzano; Giordano Nicoletti; Arianna Palladini; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Elena Raschi; Roberta Laranga; Marco Gambarotti; Piero Picci; Carla De Giovanni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Oncotarget       Date:  2014-12-15

8.  p53 and rapamycin are additive.

Authors:  Barbara Christy; Marco Demaria; Judith Campisi; Jing Huang; Diane Jones; Sherry G Dodds; Charnae Williams; Gene Hubbard; Carolina B Livi; Xiaoli Gao; Susan Weintraub; Tyler Curiel; Z Dave Sharp; Paul Hasty
Journal:  Oncotarget       Date:  2015-06-30

9.  Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).

Authors:  Olga V Leontieva; Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2015-09-15

10.  Latest progress in tyrosine kinase inhibitors.

Authors:  Tatiana V Pospelova; Valery A Pospelov
Journal:  Oncotarget       Date:  2014-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.